Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 13/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL8100 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL16766960 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29351024 | 1.00 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL574229 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4924110 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3232460 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3232064 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3637153 | 0.99 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2505835 | 0.99 | EGFR (0.97) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL18691854 | 0.99 | EGFR (0.97) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724813-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | Genentech, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260048084-A1 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | ARTIVA BIOTHERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | disclosed |
| US-12522662-B2 | Anti-PD-L1 antibody, and preparation method therefor and application thereof | SYNBIO TECHNOLOGIES LLC (CN) | 2026-01-13 | — | — | US | disclosed |
| WO-2025188783-A9 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| EP-3429571-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ORYZON GENOMICS SA (ES) | 2025-10-08 | — | — | EP | disclosed |
| EP-4572776-A2 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | Artiva Biotherapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119816313-A | Method of administering natural killer cells containing anti-human epidermal growth factor receptor 2 (HER 2) Chimeric Antigen Receptor (CAR) | 埃迪瓦生物治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119632992-A | Therapeutic compositions and methods for treating cancer | 帕特恩电脑公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2022133056-A1 | EXPANDED AND STIMULATED NATURAL KILLER CELLS | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133057-A1 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | ARTIVA BIOTHERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220184090-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | NOVARTIS AG (CH) | 2022-06-16 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3999065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022089590-A1 | COMPLEX SALT COMPOUND OF FLAVONOID GLYCOSIDE-ORGANIC AMINE TYROSINE KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州拉林智能科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| CN-114401723-A | Therapeutic compositions and methods for treating cancer | 帕特恩电脑公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220098303-A1 | COMBINATION TREATMENTS FOR CANCER COMPRISING BELANTAMAB MAFODOTIN AND AN ANTI OX40 ANTIBODY AND USES AND METHODS THEREOF | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-31 | — | — | US | disclosed |
| EP-3964513-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | Novartis AG (CH) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048084-A1 | METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR) | PBK, HAVCR2, FCGR2A | EGFR 9/4885ERBB2 11/4885ABCB11 3460/4885 |
| US-20220184090-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ABCB11 624/4885 |
| US-20220098303-A1 | COMBINATION TREATMENTS FOR CANCER COMPRISING BELANTAMAB MAFODOTIN AND AN ANTI OX40 ANTIBODY AND USES AND METHODS THEREOF | CD274, PDCD10, PDCD1 | EGFR 1180/4885ERBB2 2076/4885ABCB11 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.